Clinical study on recombinant human endostatin combined with transcatheter arterial chemoembolization in treat-ment with advancedpr imary hepait c carcinoma
ZHANG Ping
LI Chuntian
MA Ming
ZHANG Wei
Abstract：Objective To compare the clinical curative effect of recombinant human endostatin ( rh-ES) combined with transcatheter arterial chemoembolization ( TACE) and single TACE in the treatment of advanced primary hepatocellular carcinoma(PHC).Methods 85 cases of advanced PHC patients underwent TACE treatment.According to whether applied the injection of rh-ES before and after TACE, they were divided into observation group (45 cases), control group (40 cases). Two groups’ TACE postoperative curative effect in the near future were compared , serum marker [alpha fetal protein (AFP), insulin like growth factor II (IGF-II) , insulin like growth factor binding protein 2 (TGFBP-2), vascular endothelial growth factor ( VEGF) ] and chemotherapy drug adverse reaction were compared between the two groups. All patients were followed up for survival time .Results Observation group ’ s overall efficiency was 20.0%, and clinical benefit rate was 88.9%, which was higher than the 12.5% and 80.0% in the control group, the difference was not statistically significant (χ2 =0.866,χ2 =1.292, P >0.05).Compared with the preoperative, 2 months after TACE operation, serum AFP, IGF-II, IG-FBP 2 and VEGF levels were significantly decreased in both of the two groups (observation group:t =20.658, t =12.453, t=14.597, t =21.797, control group:t =15.374, t =7.950, t =10.968, t =11.091, P <0.05);after treatment, obser-vation group ’ s indexes level were significantly lower than those of the control group , the difference were statistically significant ( t =2.870, t =8.123, t =2.714, t =6.994, P <0.05).Two groups’ bone marrow suppression, gastrointestinal tract reaction, liver function damage, fever and other common toxicity reaction rate had no significant difference ( P >0.05), the observation group after injected rh-ES’ s arrhythmia occurred rate was 11.1%, which was higher than that of the control group’s 2.5%, the difference was not statistically significant ( P >0.05).The observation group and the control group after TACE’s median follow-up time was(21.0 ±1.1) months and (15.0 ±1.3) months, the difference in survival time between the two groups has statistical significance (χ2 =4.227, P =0.040).In the observation group, TACE postoperative 12 months’ survival rate was 80.0%, 24 months’ survival rate was 42.2%, which were higher than those of control group ’ s 67.5%and 27.5%, but the differences were no statistical significance (χ2 =1.725, P =0.189;χ2 =2.010, P =0.156). Conclusion Transcatheter arterial chemoembolization ( TACE) combined application of rh-ES in the treatment of advanced PHC can inhibit the formation of tumor blood vessels , improve the short-term effects and long-term survival time;toxic effects on the cardiovascular system should be noticed during using rh-ES.
Keywords：Primary hepatocellular carcinomaRecombinant human endostatinTranscatheter arterial chemoemboliza-tionAlpha fetoproteinVascular endothelial growth factorSurvival time
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 939-943 )